文献速递免疫规划慢病防控与筛查

带状疱疹疫苗接种与眼科疾病风险降低:韩国全国性模拟目标试验

Herpes zoster vaccination and the risk reduction of ophthalmic diseases: A nationwide emulated target trial in South Korea.
PubMed 文献 · Vaccine · 2026-03-02

该研究采用模拟目标试验方法,纳入韩国≥50岁人群2,519,582人,评估接种至少一剂减毒活带状疱疹疫苗与眼科疾病风险的关系。经1:1倾向评分匹配后,各组570,334人,接种组任何眼科疾病风险降低18%(aHR 0.82,95%CI 0.81-0.82),青光眼和白内障风险亦降低。保护作用在男性和<60岁人群中更明显,可持续长达八年。

要点

  • 带状疱疹疫苗接种与任何眼科疾病风险降低18%相关(aHR 0.82,95%CI 0.81-0.82)。
  • 青光眼(aHR 0.81,95%CI 0.80-0.82)和白内障(aHR 0.82,95%CI 0.82-0.83)风险降低最显著。
  • 保护作用在男性和<60岁人群中更明显,可持续长达八年,接种后1-4年获益最大。

核心结论

  • 减毒活带状疱疹疫苗接种显著降低眼科疾病发生率,尤其是青光眼和白内障,提示保护作用超出预防带状疱疹本身。

研究设计与样本

  • 韩国全国性模拟目标试验,纳入2,519,582名≥50岁个体,整合健康保险、国家健康检查和疫苗接种数据。
  • 暴露定义为2012年1月1日至2021年12月31日期间接种至少一剂减毒活带状疱疹疫苗。
  • 采用1:1倾向评分匹配后,接种组和未接种组各570,334人(平均年龄61.07岁[SD 3.48],女性54.34%)。
  • 主要结局为眼科事件,随访从索引日期至2024年1月31日,使用Cox比例风险模型估计调整风险比(aHR)及95%CI。

主要发现

  • 接种带状疱疹疫苗与任何眼科疾病风险降低18%相关(aHR 0.82,95%CI 0.81-0.82)。
  • 青光眼风险降低19%(aHR 0.81,95%CI 0.80-0.82),白内障风险降低18%(aHR 0.82,95%CI 0.82-0.83)。
  • 保护效应在男性和<60岁人群中更明显。
  • 关联可持续长达八年,接种后1至4年获益最大。

临床怎么用

  • 对于≥50岁人群,接种减毒活带状疱疹疫苗可能作为降低青光眼和白内障风险的潜在措施。
  • 在男性和<60岁人群中,疫苗接种的眼科保护作用可能更明显,可优先考虑。
  • 接种后1-4年保护效益最大,可持续长达八年,提示长期眼科健康获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent evidence has suggested that administration of the live attenuated zoster vaccine may be associated with a reduced risk of developing conditions such as dementia and cardiovascular diseases, potentially through the prevention of herpes zoster infection. This study aims to evaluate whether herpes zoster vaccination can reduce the risk of ophthalmic diseases, including glaucoma and cataract. This target trial emulation study in South Korea included 2,519,582 individuals aged ≥50 years. The cohort was established by integrating health insurance data from the Korea Health Insurance Review and Assessment Service, national health examination data from the Korean National Health Insurance Service, and vaccination data from the Korea Disease Control and Prevention Agency. Exposure was defined as receipt of at least one dose of live zoster vaccination between January 1, 2012, and December 31, 2021. The primary outcomes included ophthalmic events and follow-up extended from the index date to January 31, 2024. A propensity score-matched analysis was conducted, and Cox proportional hazards models were applied to estimate adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs). After 1:1 propensity score matching, 570,334 individuals were included in both the vaccinated and unvaccinated groups (mean age, 61.07 years [SD, 3.48]; 54.34% females). Vaccination against herpes zoster was associated with an 18% lower risk of developing any ophthalmic disease (0.82 [95% CI, 0.81-0.82]), with the strongest associations observed for glaucoma (0.81 [95% CI, 0.80-0.82]) and cataract (0.82 [95% CI, 0.82-0.83]). The protective effect was more pronounced among male and individuals aged <60 years. This association was sustained for up to eight years, with the greatest benefit observed between one and four years following vaccination. Live attenuated zoster vaccination significantly reduced the incidence of ophthalmic diseases, particularly glaucoma and cataract, indicating protective effects beyond prevention of shingles.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lee S, Lee K, Yeo D, et al. Herpes zoster vaccination and the risk reduction of ophthalmic diseases: A nationwide emulated target trial in South Korea. Vaccine. 2026. PMID: 41775120. doi:10.1016/j.vaccine.2026.128400

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。